Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi is conducting a study titled ‘A Phase 2b/3, Randomized, ...

New findings from the ERS Global Congress on Lung Diseases present a paradigm shift in COPD treatment: Early identification of type 2 inflammation and personalized biologic therapy.

PHILADELPHIA (WPVI) -- COPD is one of the nation's biggest health problems - up to 24 million Americans may suffer from it. Temple Health is involved in trials for an innovative treatment to cut COPD ...

Providence Holy Cross Medical Center is the first Providence hospital in the San Fernando Valley to offer a minimally ...

Dedicated COPD respiratory therapists can improve inhaler use, ensure adherence, and bridge care transitions, explained Megan ...

CHICAGO, July 8, 2025 /PRNewswire/ -- The American Lung Association is launching a new campaign to support and empower individuals living with chronic obstructive pulmonary disease (COPD) in rural and ...

In Canada, Dupixent® has received regulatory approvals for certain patients in the following indications atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic ...

Among adults with COPD and type 2 inflammation, having a history of cardiovascular or metabolic disease did not change ...

In one of the biggest health care deals of 2025, the pharmaceutical giant Merck has acquired the British drugmaker Verona Pharma for roughly $10 billion. Merck announced its purchase of the publicly ...

Using a care pathway focused on chronic obstructive pulmonary disease (COPD) can lead to shorter hospital stays, increased referrals to pulmonary rehabilitation, and improved standardization of care, ...

The FDA accepted a new drug application for a single inhaler that contains beclomethasone dipropionate, formoterol fumarate ...